Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Accounts Payables: 2023-2024

Historic Accounts Payables for Contineum Therapeutics (CTNM) over the last 2 years, with Dec 2024 value amounting to $1.8 million.

  • Contineum Therapeutics' Accounts Payables fell 43.74% to $786,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $786,000, marking a year-over-year decrease of 43.74%. This contributed to the annual value of $1.8 million for FY2024, which is 185.20% up from last year.
  • As of FY2024, Contineum Therapeutics' Accounts Payables stood at $1.8 million, which was up 185.20% from $635,000 recorded in FY2023.
  • Contineum Therapeutics' Accounts Payables' 5-year high stood at $1.8 million during FY2024, with a 5-year trough of $635,000 in FY2023.
  • For the 2-year period, Contineum Therapeutics' Accounts Payables averaged around $1.2 million, with its median value being $1.2 million (2023).
  • Data for Contineum Therapeutics' Accounts Payables shows a peak YoY spiked of 185.20% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Contineum Therapeutics' Accounts Payables stood at $635,000 in 2023, then spiked by 185.20% to $1.8 million in 2024.